Kedrion IVIG 10% ( DrugBank: IVIg )

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	3

65. Primary immunodeficiency

Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04944979 (ClinicalTrials.gov)	March 31, 2021	11/6/2021	Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients ...	A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokine ...	Primary Immunodeficiency Disease	Biological: Kedrion IVIG 10%	Kedrion S.p.A.	NULL	Recruiting	2 Years	16 Years	All	30	Phase 3	Hungary;Italy;Slovakia
2	NCT03961009 (ClinicalTrials.gov)	April 30, 2019	21/5/2019	Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients	A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinet ...	Primary Immunodeficiency Disease	Biological: Kedrion IVIG 10%	Kedrion S.p.A.	NULL	Completed	2 Years	70 Years	All	47	Phase 3	United States;Canada
3	NCT01581593 (ClinicalTrials.gov)	November 2012	16/4/2012	Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)	Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerabili ...	Primary Immunodeficiency;Agammaglobulinemia;Hypogammaglobulinemia;Antibody Deficiency	Biological: Kedrion IVIG 10%	Kedrion S.p.A.	NULL	Active, not recruiting	2 Years	70 Years	Both	50	Phase 3	United States;Canada

First Previous1Next Last